Your browser doesn't support javascript.
CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity.
Doehn, Jan-Moritz; Tabeling, Christoph; Biesen, Robert; Saccomanno, Jacopo; Madlung, Elena; Pappe, Eva; Gabriel, Frieder; Kurth, Florian; Meisel, Christian; Corman, Victor M; Hanitsch, Leif G; Treskatsch, Sascha; Heim, Kathrin; Stegemann, Miriam S; Ruwwe-Glösenkamp, Christoph; Müller-Redetzky, Holger C; Uhrig, Alexander; Somasundaram, Rajan; Spies, Claudia; von Bernuth, Horst; Hofmann, Jörg; Drosten, Christian; Suttorp, Norbert; Witzenrath, Martin; Sander, Leif E; Hübner, Ralf-Harto.
  • Doehn JM; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
  • Tabeling C; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
  • Biesen R; Division of Pulmonary Inflammation, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Saccomanno J; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Madlung E; Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Pappe E; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
  • Gabriel F; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
  • Kurth F; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
  • Meisel C; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
  • Corman VM; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
  • Hanitsch LG; Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
  • Treskatsch S; Institute of Medical Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Heim K; Labor Berlin GmbH, Berlin, Germany.
  • Stegemann MS; Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Ruwwe-Glösenkamp C; German Centre for Infection Research (DZIF), Berlin, Germany.
  • Müller-Redetzky HC; Institute of Medical Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Uhrig A; Department of Anesthesiology and Intensive Care Medicine, Charité Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Somasundaram R; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
  • Spies C; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
  • von Bernuth H; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
  • Hofmann J; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
  • Drosten C; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
  • Suttorp N; Emergency Department, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Witzenrath M; Department of Anesthesiology and Intensive Care Medicine, Charité Campus Mitte and Campus-Virchow-Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Sander LE; Department of Pediatric Pneumology, Immunology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Hübner RH; Labor Berlin GmbH, Berlin, Germany.
Infection ; 49(4): 757-762, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1171404
Semantic information from SemMedBD (by NLM)
1. SIGLEC1 gene|SIGLEC1 INTERACTS_WITH Monocytes
Subject
SIGLEC1 gene|SIGLEC1
Predicate
INTERACTS_WITH
Object
Monocytes
2. Severe infection PROCESS_OF Patients
Subject
Severe infection
Predicate
PROCESS_OF
Object
Patients
3. Patients LOCATION_OF Interferon Type I
Subject
Patients
Predicate
LOCATION_OF
Object
Interferon Type I
4. Severe disease PROCESS_OF Patients
Subject
Severe disease
Predicate
PROCESS_OF
Object
Patients
5. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
6. Interferon Signaling Process PROCESS_OF Patients
Subject
Interferon Signaling Process
Predicate
PROCESS_OF
Object
Patients
7. Patients LOCATION_OF SIGLEC1 gene|SIGLEC1
Subject
Patients
Predicate
LOCATION_OF
Object
SIGLEC1 gene|SIGLEC1
8. SIGLEC1 gene|SIGLEC1 INTERACTS_WITH Monocytes
Subject
SIGLEC1 gene|SIGLEC1
Predicate
INTERACTS_WITH
Object
Monocytes
9. Severe infection PROCESS_OF Patients
Subject
Severe infection
Predicate
PROCESS_OF
Object
Patients
10. Patients LOCATION_OF Interferon Type I
Subject
Patients
Predicate
LOCATION_OF
Object
Interferon Type I
11. Severe disease PROCESS_OF Patients
Subject
Severe disease
Predicate
PROCESS_OF
Object
Patients
12. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
13. Interferon Signaling Process PROCESS_OF Patients
Subject
Interferon Signaling Process
Predicate
PROCESS_OF
Object
Patients
14. Patients LOCATION_OF SIGLEC1 gene|SIGLEC1
Subject
Patients
Predicate
LOCATION_OF
Object
SIGLEC1 gene|SIGLEC1
ABSTRACT
Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I interferons are important in the defense of viral infections. Recently, neutralizing IgG auto-antibodies against type I interferons were found in patients with severe COVID-19 infection. Here, we analyzed expression of CD169/SIGLEC1, a well described downstream molecule in interferon signaling, and found increased monocytic CD169/SIGLEC1 expression levels in patients with mild, acute COVID-19, compared to patients with severe disease. We recommend further clinical studies to evaluate the value of CD169/SIGLEC1 expression in patients with COVID-19 with or without auto-antibodies against type I interferons.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Monocytes / Sialic Acid Binding Ig-like Lectin 1 / SARS-CoV-2 / COVID-19 Subject: Monocytes / Sialic Acid Binding Ig-like Lectin 1 / SARS-CoV-2 / COVID-19 Type of study: Observational study / Risk factors Language: English Journal: Infection Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Monocytes / Sialic Acid Binding Ig-like Lectin 1 / SARS-CoV-2 / COVID-19 Subject: Monocytes / Sialic Acid Binding Ig-like Lectin 1 / SARS-CoV-2 / COVID-19 Type of study: Observational study / Risk factors Language: English Journal: Infection Year: 2021
...